This site is intended for healthcare professionals only

SGLT inhibitors for type 1 diabetes: a finely balanced matter?

Written by: | Published:

diabetes test SGLT-2 inhibitors might also be effective glucose-lowering agents in type 1 diabetes

The utilisation of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for type 2 diabetes (T2DM) in primary care has increased dramatically since dapagliflozin first became available in the UK in November 2012. The mechanism of action of SGLT-2 inhibitors suggested that they might also be effective glucose-lowering agents in type 1 diabetes (T1DM) and emerging evidence in the last few years supports this concept.

This article reviews the evidence supporting use of SGLT inhibitors in T1DM and the risks associated with their use, most notably that of diabetic ketoacidosis (DKA). The practicalities of selecting and managing individuals suitable for treatment with SGLT inhibitors are addressed in light of recent NICE guidance on dapagliflozin and sotagliflozin.1,2


Please login or register to read the rest of the article and to have access to downloads and comments.


What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.

Newsletter

Sign up to the newsletter

About

Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.

Newsletter

Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.

Archive

Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team

Authors

Find out how to contribute to Independent Nurse here.